US Appeals Court Rules Gemzar® Patent Invalid Affirms the District Court Judgment Sun Pharma, though not a first filer, triggered this successful patent challenge

Mumbai, July 29, 2010: Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 (“’826 patent”) invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma’s submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.

In the Michigan lawsuit, Eli Lilly had contented that Sun Pharma’s ANDA infringed certain claims from the ’826 patent and U.S. Patent No. 4,808,614 (“’614 patent”) that describe gemcitabine and its uses, the active ingredient in Gemzar®. Earlier the Michigan District Court had ruled against Eli Lily stating that the asserted claims of the ’826 patent are invalid for obviousness-type double patenting over U.S. Patent No. 4,808,614 (“’614 patent”). The Appeals Court agreed with the ruling of the District Court, and noted that the Michigan Court had correctly followed the Federal Circuit’s precedent regarding double patenting. The ’826 patent, now ruled invalid, would have expired on November 7, 2012, and would have had pediatric exclusivity through May 7, 2013.

The ’614 patent, not part of the appeal, expired on May 15, 2010, but has pediatric exclusivity through November 15, 2010.

Gemzar® is a registered trademark of Eli Lilly and Co.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

You have received this email as your address is part of our Investor Relations and Media Contacts list. All our Press Releases and Financial updates are sent to those on the list.
If you wish to be removed from this list or your address has been accidentally included here, then please let us know by a return email and we will remove it. All the others will continue to be on the mailing list.
If you wish to receive emails on some other email id, please send it to us.
If you think that somebody else from your organisation should be added to this list, then please ask him / her to send us an email and we will add.